Search - tctmd.com

Displaying 81 - 100 of 240

Sort: Relevancy | Date

Presentation TCT 2014

Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate?

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Freek W.A. Verheugt

September 14, 2014

Presentation TCT 2014

Featured Lecture: First Presentation of the PLATO Primary PCI Subgroup

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Philippe Gabriel Steg

September 14, 2014

Presentation TCT 2014

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Matthew J. Price

September 14, 2014

Presentation TCT 2014

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Anthony A. Bavry

September 14, 2014

Presentation TCT 2014

TCT 481: Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus-Eluting Stent Implantation in OPTIMIZE

Presenter: Dietmar Trenk, Harvey D. White, Dominick J. Angiolillo, Fausto Feres

September 14, 2014

Presentation TCT 2014

TCT 479: The Increased Risk of Stent Thrombosis in Acute Coronary Syndromes Is Confined to the First 30 Days After PCI: Results from the Multicenter ADAPT-DES Study

Presenter: Dietmar Trenk, Harvey D. White, Dominick J. Angiolillo, Ajay J. Kirtane

September 14, 2014

Presentation TCT 2014

Time to Move to 3-6 Months Even in ACS!

Presenter: Marco Valgimigli

September 14, 2014

Presentation TCT 2014

TCT 467: Bivalirudin vs Heparin for Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Controlled Trials

Presenter: David J. Moliterno, E. Magnus Ohman, Duane S. Pinto, Michael Lipinski

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Heparin!

Presenter: Rod H. Stables

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Bivalirudin!

Presenter: Gregg W. Stone

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Heparin!

Presenter: Stefanie Schüpke

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Bivalirudin!

Presenter: Roxana Mehran

September 14, 2014

Presentation TCT 2014

Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes

Presenter: Kishore J. Harjai, Michael S. Lee

September 14, 2014

Presentation TCT 2014

Aspirin and ADP Antagonists Before and After Coronary Stent Implantation

Presenter: Paul A. Gurbel, Dmitriy N. Feldman

September 14, 2014

News Conference News TCT 2014

EUROMAX Substudy: Bivalirudin Noninferior to Heparin Plus GPI for Myocardial Reperfusion

September 14, 2014

Presentation TCT 2014

Role of New Oral Anticoagulants and New ADP Antagonists in ACS Patients

Presenter: Roxana Mehran, Mohamed Sobhy

September 13, 2014

Presentation TCT 2014

Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients with ACS and in Those Undergoing PCI

Presenter: Frederick Feit, Sripal Bangalore

September 13, 2014

Presentation TCT 2014

Optimal Duration of DAPT After Intracoronary Stenting: Current Status

Presenter: Roxana Mehran

September 13, 2014

Presentation TCT 2014

Are GP IIb/IIIa Inhibitors Still Useful?

Presenter: Marco Valgimigli

September 13, 2014

News Conference News TCT 2014

Meta-analysis: Less Bleeding, More Stent Thrombosis with Bivalirudin vs. Heparin After PCI

September 13, 2014

Advertisement

Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate?

Featured Lecture: First Presentation of the PLATO Primary PCI Subgroup

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

TCT 481: Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus-Eluting Stent Implantation in OPTIMIZE

TCT 479: The Increased Risk of Stent Thrombosis in Acute Coronary Syndromes Is Confined to the First 30 Days After PCI: Results from the Multicenter ADAPT-DES Study

Time to Move to 3-6 Months Even in ACS!

TCT 467: Bivalirudin vs Heparin for Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Controlled Trials

The Data Strongly Support Heparin!

The Data Strongly Support Bivalirudin!

The Data Strongly Support Heparin!

The Data Strongly Support Bivalirudin!

Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes

Aspirin and ADP Antagonists Before and After Coronary Stent Implantation

EUROMAX Substudy: Bivalirudin Noninferior to Heparin Plus GPI for Myocardial Reperfusion

Role of New Oral Anticoagulants and New ADP Antagonists in ACS Patients

Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients with ACS and in Those Undergoing PCI

Optimal Duration of DAPT After Intracoronary Stenting: Current Status

Are GP IIb/IIIa Inhibitors Still Useful?

Meta-analysis: Less Bleeding, More Stent Thrombosis with Bivalirudin vs. Heparin After PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content